MYO1B: A Protein Crucial for Muscle Contraction and Relaxation, Now A Drug Target and Biomarker

Target Name: MYO1B

NCBI ID: G4430

MYO1B

MYO1B: A Protein Crucial for Muscle Contraction and Relaxation, Now A Drug Target and Biomarker

Myosin-Ib (ISOform 2) is a protein that plays a crucial role in muscle contraction and relaxation. It is a key component of the myosin filament, which is the protein complex that powers muscle contractions. Myosin-Ib is known for its unusual structure, which consists of a long alpha-helices and a short beta-sheet. This unique configuration has led to its nickname, \"unconventional myosin-Ib.\"

MYO1B as a drug target

The search for new drug targets has led to the identification of MYO1B as a potential therapeutic target for a variety of muscle-related conditions. Its unique structure and function have made it an attractive target for drug developers due to its potential to modulate muscle contractions and improve muscle function.

MYO1B as a biomarker

In addition to its potential as a drug target,MYO1B has also been identified as a potential biomarker for several muscle-related conditions. Its unique structure and function make it a potential marker for muscle aging, muscle disease, and muscle injury.

MYO1B as a target for drug development

One of the main goals of drug development is to identify compounds that can modulate the activity of a protein and improve its function. This is the case with MYO1B, which has been identified as a potential drug target.

MYO1B has been shown to play a role in muscle contractions and relaxation. It is a key component of the myosin filament, which is the protein complex that powers muscle contractions. By modulating the activity of MYO1B, researchers have been able to improve muscle function and reduce muscle damage.

MYO1B has also been shown to be involved in the regulation of muscle growth and aging. Its unique structure and function make it a potential target for compounds that can promote muscle growth and reduce muscle aging.

MYO1B as a biomarker

In addition to its potential as a drug target,MYO1B has also been identified as a potential biomarker for several muscle-related conditions. Its unique structure and function make it a potential marker for muscle aging, muscle disease, and muscle injury.

MYO1B has been shown to play a role in the regulation of muscle contractions and relaxation. It is a key component of the myosin filament, which is the protein complex that powers muscle contractions. By modulating the activity of MYO1B, researchers have been able to improve muscle function and reduce muscle damage.

MYO1B has also been shown to be involved in the regulation of muscle growth and aging. Its unique structure and function make it a potential target for compounds that can promote muscle growth and reduce muscle aging.

Conclusion

MYO1B is a protein that plays a crucial role in muscle contraction and relaxation. Its unique structure and function have led to its nickname, \"unconventional myosin-Ib.\" The search for new drug targets has led to the identification of MYO1B as a potential therapeutic target for a variety of muscle-related conditions. Its potential as a biomarker for muscle aging, muscle disease, and muscle injury makes it an attractive target for drug developers. As research continues to uncover the unique functions of MYO1B, it is clear that it will be an important player in the field of muscle biology and the development of new treatments for muscle-related conditions.

Protein Name: Myosin IB

Functions: Motor protein that may participate in process critical to neuronal development and function such as cell migration, neurite outgrowth and vesicular transport

The "MYO1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYO1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets